Immunic (IMUX) Net Equity Issued and Repurchased (2016 - 2024)

Immunic (IMUX) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $191000.0 in Q1 2024.

• For the quarter ending Q1 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $191000.0; the trailing twelve-month figure through Dec 2024 stood at $191000.0 (down 78.07% YoY), and the FY2024 full-year result was $191000.0, down 77.61% from the prior year.
• Net Equity Issued and Repurchased eased to $191000.0 in Q1 2024, from $571000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $73.5 million in Q4 2020 to a low of -$41.3 million in Q4 2021.
• A 5-year average of $12.5 million and a median of $2.2 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased surged 9355.14% in 2020 and tumbled 156.18% in 2021, its largest moves.
• Tracing IMUX's Net Equity Issued and Repurchased over 5 years: stood at $73.5 million in 2020, then plunged by 156.18% to -$41.3 million in 2021, then jumped by 100.04% to $16000.0 in 2022, then soared by 3468.75% to $571000.0 in 2023, then tumbled by 66.55% to $191000.0 in 2024.
• Business Quant data shows IMUX's Net Equity Issued and Repurchased at $191000.0 in Q1 2024, $571000.0 in Q4 2023, and $300000.0 in Q3 2023.